Eli Lilly and Company (LLY) Management Presents at UBS Global Healthcare Conference (Transcript)

Summary of Eli Lilly and Company (NYSE: LLY) at UBS Global Healthcare Conference Company Overview - Company: Eli Lilly and Company - Event: UBS Global Healthcare Conference - Date: May 24, 2022 - Key Participant: Mike Mason, President of Lilly Diabetes Key Points Industry and Product Focus - Diabetes and Obesity Treatment: Eli Lilly is focusing on diabetes and obesity treatments, particularly through its products Jardiance and Mounjaro [3][4][83]. Jardiance Performance - Market Share: Jardiance has achieved a new treatment share market above 64% and has seen close to 30% year-on-year growth [3][4]. - Product Expansion: The product is being positioned not only for Type 2 diabetes but also for cardiovascular issues and chronic kidney disease (CKD) [3]. Mounjaro Launch Strategy - Approval and Efficacy: Mounjaro has been approved for Type 2 diabetes, showing significant weight loss of up to 52 pounds in a 72-week study [4][29]. - Target Market: The launch strategy focuses on patients who are out of control with their diabetes, rather than switching existing patients from Trulicity [6][7]. - Pricing Strategy: Mounjaro is priced approximately 9.9% above Trulicity, with a focus on balancing value and broad access [8][10]. Market Access and Payer Engagement - Formulary Access: Discussions with payers are ongoing, and the company is optimistic about gaining broad access at the set price point [14]. - Patient Support Programs: Eli Lilly plans to implement support programs, including a $25 co-pay card and month-long samples, to facilitate patient access [17][18]. Competitive Landscape - Cannibalization Concerns: There is an acknowledgment of potential cannibalization of Trulicity sales by Mounjaro, but the focus remains on establishing Mounjaro as a long-term solution for Type 2 diabetes [22][24]. - Market Dynamics: The company is aware of the competitive landscape, particularly with Novo Nordisk's products, and aims to differentiate Mounjaro based on its unique benefits [41][45]. Future Developments - Obesity Indication: Eli Lilly is preparing for a filing for obesity indication in 2024, with ongoing trials (SURMOUNT-2, 3, and 4) expected to provide additional data [31][32]. - NASH Trials: The company is conducting Phase II trials for NASH, exploring the potential benefits of tirzepatide in reducing liver fat [70]. Market Trends and Challenges - SGLT2 Market Growth: The SGLT2 class is experiencing growth, particularly in heart failure and CKD, with a noted increase in market share [73]. - Pricing Pressures: There are ongoing discussions about pricing dynamics in the insulin and GLP-1 markets, with expectations of continued competition and potential pricing pressures [52][54]. Closing Remarks - Transformative Potential: Eli Lilly expresses confidence in the transformative potential of Mounjaro and its ability to address significant health needs in diabetes and obesity [83]. This summary encapsulates the key insights from the conference, highlighting Eli Lilly's strategic focus on diabetes and obesity treatments, market positioning, and future growth opportunities.